Accessibility Menu
 
bioAffinity Technologies logo

bioAffinity Technologies

(NASDAQ) BIAF

Current Price$3.89
Market Cap$17.63M
Since IPO (2022)-98%
5 YearN/A
1 Year-85%
1 Month+312%

bioAffinity Technologies Financials at a Glance

Market Cap

$17.63M

Revenue (TTM)

$6.16M

Net Income (TTM)

$14.91M

EPS (TTM)

$-15.41

P/E Ratio

-0.25

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$3.89

Volume

1,455,888.466

Open

$3.74

Previous Close

$3.92

Daily Range

$3.59 - $4.09

52-Week Range

$0.69 - $23.38

BIAF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About bioAffinity Technologies

Industry

Biotechnology

Employees

57

CEO

Maria Zannes

Headquarters

San Antonio, TX 78257, US

BIAF Financials

Key Financial Metrics (TTM)

Gross Margin

23%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-302%

Return on Capital

-1%

Return on Assets

-1%

Earnings Yield

-4.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.63M

Shares Outstanding

4.50M

Volume

1.46M

Short Interest

0.00%

Avg. Volume

8.60M

Financials (TTM)

Gross Profit

$1.43M

Operating Income

$10.57M

EBITDA

$10.07M

Operating Cash Flow

$9.33M

Capital Expenditure

$60.57K

Free Cash Flow

$9.39M

Cash & ST Invst.

$6.45M

Total Debt

$1.16M

bioAffinity Technologies Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.59M

-27.8%

Gross Profit

$301.21K

-38.8%

Gross Margin

18.91%

N/A

Market Cap

$17.63M

N/A

Market Cap/Employee

$309.38K

N/A

Employees

57

N/A

Net Income

$3.14M

-5.7%

EBITDA

$3.01M

-8.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$5.29M

+1435.9%

Accounts Receivable

$541.96K

-52.4%

Inventory

$53.55K

+94.0%

Long Term Debt

$776.95K

-3.7%

Short Term Debt

$383.87K

-44.7%

Return on Assets

-1.36%

N/A

Return on Invested Capital

-1.31%

N/A

Free Cash Flow

$2.50M

-49.0%

Operating Cash Flow

$2.56M

-52.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTLArtelo Biosciences, Inc.
$7.04-10.20%
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
GTBPGT Biopharma, Inc.
$0.45+9.79%
REVBRevelation Biosciences, Inc.
$1.25+1.63%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NOKNokia
$8.82+0.07%

Questions About BIAF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.